434 related articles for article (PubMed ID: 32333549)
21. Interlink Between Insulin Resistance and Neurodegeneration with an Update on Current Therapeutic Approaches.
Bhattamisra SK; Shin LY; Saad HIBM; Rao V; Candasamy M; Pandey M; Choudhury H
CNS Neurol Disord Drug Targets; 2020; 19(3):174-183. PubMed ID: 32418534
[TBL] [Abstract][Full Text] [Related]
22. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
Ferrari F; Moretti A; Villa RF
Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
[TBL] [Abstract][Full Text] [Related]
23. The Impact of Type 2 Diabetes in Parkinson's Disease.
Athauda D; Evans J; Wernick A; Virdi G; Choi ML; Lawton M; Vijiaratnam N; Girges C; Ben-Shlomo Y; Ismail K; Morris H; Grosset D; Foltynie T; Gandhi S
Mov Disord; 2022 Aug; 37(8):1612-1623. PubMed ID: 35699244
[TBL] [Abstract][Full Text] [Related]
24. Exploring the link between Parkinson's disease and type 2 diabetes mellitus in Drosophila.
Sanz FJ; Solana-Manrique C; Lilao-Garzón J; Brito-Casillas Y; Muñoz-Descalzo S; Paricio N
FASEB J; 2022 Aug; 36(8):e22432. PubMed ID: 35766235
[TBL] [Abstract][Full Text] [Related]
25. Development of Dementia in Type 2 Diabetes Patients: Mechanisms of Insulin Resistance and Antidiabetic Drug Development.
Singh DD; Shati AA; Alfaifi MY; Elbehairi SEI; Han I; Choi EH; Yadav DK
Cells; 2022 Nov; 11(23):. PubMed ID: 36497027
[TBL] [Abstract][Full Text] [Related]
26. Neuroendocrine abnormalities in Parkinson's disease.
De Pablo-Fernández E; Breen DP; Bouloux PM; Barker RA; Foltynie T; Warner TT
J Neurol Neurosurg Psychiatry; 2017 Feb; 88(2):176-185. PubMed ID: 27799297
[TBL] [Abstract][Full Text] [Related]
27. NF-κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective.
Alrouji M; Al-Kuraishy HM; Al-Gareeb AI; Alexiou A; Papadakis M; Jabir MS; Saad HM; Batiha GE
J Cell Mol Med; 2023 Jul; 27(13):1775-1789. PubMed ID: 37210624
[TBL] [Abstract][Full Text] [Related]
28. Diabetes, insulin and new therapeutic strategies for Parkinson's disease: Focus on glucagon-like peptide-1 receptor agonists.
Labandeira CM; Fraga-Bau A; Arias Ron D; Muñoz A; Alonso-Losada G; Koukoulis A; Romero-Lopez J; Rodriguez-Perez AI
Front Neuroendocrinol; 2021 Jul; 62():100914. PubMed ID: 33845041
[TBL] [Abstract][Full Text] [Related]
29. Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson's disease.
Pezzoli G; Cereda E; Calandrella D; Barichella M; Bonvegna S; Isaias IU
Clin Nutr ESPEN; 2024 Apr; 60():309-312. PubMed ID: 38479927
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review.
Mahapatra MK; Karuppasamy M; Sahoo BM
Pharm Res; 2022 Jun; 39(6):1233-1248. PubMed ID: 35650449
[TBL] [Abstract][Full Text] [Related]
31. Protective effects of the GLP-1 mimetic exendin-4 in Parkinson's disease.
Athauda D; Foltynie T
Neuropharmacology; 2018 Jul; 136(Pt B):260-270. PubMed ID: 28927992
[TBL] [Abstract][Full Text] [Related]
32. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
Batista AF; Bodart-Santos V; De Felice FG; Ferreira ST
CNS Drugs; 2019 Mar; 33(3):209-223. PubMed ID: 30511349
[TBL] [Abstract][Full Text] [Related]
33. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
Hölscher C
Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
[TBL] [Abstract][Full Text] [Related]
34. A zebrafish screen reveals Renin-angiotensin system inhibitors as neuroprotective via mitochondrial restoration in dopamine neurons.
Kim GJ; Mo H; Liu H; Wu Z; Chen S; Zheng J; Zhao X; Nucum D; Shortland J; Peng L; Elepano M; Tang B; Olson S; Paras N; Li H; Renslo AR; Arkin MR; Huang B; Lu B; Sirota M; Guo S
Elife; 2021 Sep; 10():. PubMed ID: 34550070
[TBL] [Abstract][Full Text] [Related]
35. The Contribution of Type 2 Diabetes to Parkinson's Disease Aetiology.
Ribarič S
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673943
[TBL] [Abstract][Full Text] [Related]
36. Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease.
Yarchoan M; Arnold SE
Diabetes; 2014 Jul; 63(7):2253-61. PubMed ID: 24931035
[TBL] [Abstract][Full Text] [Related]
37. Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications.
Hassan A; Sharma Kandel R; Mishra R; Gautam J; Alaref A; Jahan N
Cureus; 2020 Aug; 12(8):e9853. PubMed ID: 32832307
[TBL] [Abstract][Full Text] [Related]
38. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
[TBL] [Abstract][Full Text] [Related]
39. Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression.
Chohan H; Senkevich K; Patel RK; Bestwick JP; Jacobs BM; Bandres Ciga S; Gan-Or Z; Noyce AJ
Mov Disord; 2021 Jun; 36(6):1420-1429. PubMed ID: 33682937
[TBL] [Abstract][Full Text] [Related]
40. Onset and mortality of Parkinson's disease in relation to type II diabetes.
Pezzoli G; Cereda E; Amami P; Colosimo S; Barichella M; Sacilotto G; Zecchinelli A; Zini M; Ferri V; Bolliri C; Calandrella D; Bonelli MG; Cereda V; Reali E; Caronni S; Cassani E; Canesi M; Del Sorbo F; Soliveri P; Zecca L; Klersy C; Cilia R; Isaias IU
J Neurol; 2023 Mar; 270(3):1564-1572. PubMed ID: 36436068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
